BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 34600554)

  • 1. Responsiveness and convergent validity of QLU-C10D and EQ-5D-3L in assessing short-term quality of life following esophagectomy.
    Bulamu NB; Vissapragada R; Chen G; Ratcliffe J; Mudge LA; Smithers BM; Isenring EA; Smith L; Jamieson GG; Watson DI;
    Health Qual Life Outcomes; 2021 Oct; 19(1):233. PubMed ID: 34600554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L.
    Gamper EM; Cottone F; Sommer K; Norman R; King M; Breccia M; Caocci G; Patriarca A; Palumbo GA; Stauder R; Niscola P; Platzbecker U; Caers J; Vignetti M; Efficace F
    J Clin Epidemiol; 2021 Sep; 137():31-44. PubMed ID: 33753228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs.
    Pilz MJ; Seyringer S; Al-Naesan I; King MT; Bottomley A; Norman R; Schlosser L; Hell T; Gamper EM;
    Pharmacoecon Open; 2024 May; ():. PubMed ID: 38696019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
    Shaw JW; Bennett B; Trigg A; DeRosa M; Taylor F; Kiff C; Ntais D; Noon K; King MT; Cocks K
    Value Health; 2021 Nov; 24(11):1651-1659. PubMed ID: 34711366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands.
    Pilz MJ; Seyringer S; Hallsson LR; Bottomley A; Jansen F; King MT; Norman R; Rutten MJ; Leeuw IMV; Siersema PD; Gamper EM
    Eur J Health Econ; 2024 Mar; ():. PubMed ID: 38483665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis.
    Kim H; Cook G; Goodall S; Liew D
    Pharmacoecon Open; 2021 Sep; 5(3):459-467. PubMed ID: 33891268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of Health-Related Utilities for
    Soare IA; Leeuwenkamp O; Longworth L
    Pharmacoecon Open; 2021 Dec; 5(4):715-725. PubMed ID: 34260017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients.
    Pan CW; He JY; Zhu YB; Zhao CH; Luo N; Wang P
    Eur J Health Econ; 2023 Aug; 24(6):885-893. PubMed ID: 36083356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The EQ-5D-5L Is Superior to the -3L Version in Measuring Health-related Quality of Life in Patients Awaiting THA or TKA.
    Jin X; Al Sayah F; Ohinmaa A; Marshall DA; Smith C; Johnson JA
    Clin Orthop Relat Res; 2019 Jul; 477(7):1632-1644. PubMed ID: 30801280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30.
    King MT; Viney R; Simon Pickard A; Rowen D; Aaronson NK; Brazier JE; Cella D; Costa DSJ; Fayers PM; Kemmler G; McTaggart-Cowen H; Mercieca-Bebber R; Peacock S; Street DJ; Young TA; Norman R;
    Pharmacoeconomics; 2018 Feb; 36(2):225-238. PubMed ID: 29270835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health utility assessments in individuals undergoing diagnostic and surveillance colonoscopy: improved discrimination with a cancer-specific scale.
    Bulamu NB; Chen G; McGrane E; Cock C; Young GP; Symonds EL
    Cancer Causes Control; 2024 Feb; 35(2):347-357. PubMed ID: 37747615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health state utility differed systematically in breast cancer patients between the EORTC QLU-C10D and the PROMIS Preference Score.
    Klapproth CP; Fischer F; Rose M; Karsten MM
    J Clin Epidemiol; 2022 Dec; 152():101-109. PubMed ID: 36162712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population.
    Selva-Sevilla C; Ferrara P; Gerónimo-Pardo M
    Eur J Health Econ; 2020 Jun; 21(4):649-662. PubMed ID: 32065301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convergent and Discriminant Validity of the Barthel Index and the EQ-5D-3L When Used on Older People in a Rehabilitation Setting.
    Kaambwa B; Bulamu NB; Mpundu-Kaambwa C; Oppong R
    Int J Environ Res Public Health; 2021 Sep; 18(19):. PubMed ID: 34639614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. French Value-Set of the QLU-C10D, a Cancer-Specific Utility Measure Derived from the QLQ-C30.
    Nerich V; Gamper EM; Norman R; King M; Holzner B; Viney R; Kemmler G
    Appl Health Econ Health Policy; 2021 Mar; 19(2):191-202. PubMed ID: 32537694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The feasibility, repeatability, validity and responsiveness of the EQ-5D-3L in Krio for patients with stroke in Sierra Leone.
    Youkee D; Pessima S; Sackley C; Soley-Bori M; Deen GF; Marshall IJ
    Health Qual Life Outcomes; 2024 Mar; 22(1):29. PubMed ID: 38549069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing EQ-5D-3L and EQ-5D-5L performance in common cancers: suggestions for instrument choosing.
    Zhu J; Yan XX; Liu CC; Wang H; Wang L; Cao SM; Liao XZ; Xi YF; Ji Y; Lei L; Xiao HF; Guan HJ; Wei WQ; Dai M; Chen W; Shi JF
    Qual Life Res; 2021 Mar; 30(3):841-854. PubMed ID: 32930993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement properties of EQ-5D-3L and EQ-5D-5L in recording self-reported health status in older patients with substantial multimorbidity and polypharmacy.
    Bhadhuri A; Kind P; Salari P; Jungo KT; Boland B; Byrne S; Hossmann S; Dalleur O; Knol W; Moutzouri E; O'Mahony D; Murphy KD; Wisselink L; Rodondi N; Schwenkglenks M
    Health Qual Life Outcomes; 2020 Sep; 18(1):317. PubMed ID: 32993637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
    Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
    J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
    Cheung PWH; Wong CKH; Cheung JPY
    Spine (Phila Pa 1976); 2019 Jun; 44(11):E679-E686. PubMed ID: 30475342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.